Pages

Monday, April 28, 2014

Big De-Risking of ALN-TTR02 and SNALP Delivery Platform

Today, Alnylam reported (PR here, presentation here) first data from its phase II open-label
extension study of ALN-TTR02. ALN-TTR02 is developed for the treatment of TTR amyloidosis (FAP
form) and with a phase III study underway is the industry’s lead blockbuster candidate. There is no doubt that its results will
have a big impact on the perception of the technology. Importantly, the new data revealed at the International Symposium on Amyloidosis show that ALN-TT02 not only maintains consistent knockdown
potency following multiple (>2) administrations, but even more importantly,
indicate that the biggest risk, long-term safety, will not be a problem.

Phase II promising, but with efficacy and safety
questions

The new data follow on from a 2-dose phase II study (somewhat euphemistically labeled 'repeat administration) showing
that ALN-TTR02 can achieve ~80% TTR knockdown levels not only following a first
dose, but also
following a second dose. This was good
to see because there was theoretical concern that SNALP LNPs could provoke generation of neutralizing antibodies to the PEG component which might compromise efficacy
following repeat dosing. Indeed, TTR
levels seemed to return back to normal more quickly following the second
compared to the first dose and was responsible for Alnylam switching from a 3-week to a 4-week dosing interval.

On the safety side, infusion-related hypersensitivity
reactions are the major concern with SNALP LNP as with most other infused
therapeutics, nucleic acids, protein, or small molecules alike. While the steroid pre-treatment may have
ensured that no major immune reaction was seen in the phase II study, infusion
reactions had been recorded in 3 of 20 infusions at the key 0.3mg/kg dose. Intriguingly, when a micro-dosing
pre-treatment strategy was employed (increasing the length of infusion from 60 to 70 minutes) no such reactions were seen in the 18 infusions thus administered. This is probably related to the fact that infusion reactions in
general are essentially restricted to the first dose and are dose-related.

Phase II open-label extension data provide highly
positive answers

In thinking about a headline for today’s blog entry ‘spectacular’
was on my mind a lot. However, I refrained from
using this term as the scientific results show very comforting consistency. 'Spectacular consistency' may be too oxymoronic. In stock market terms, however, this consistency
may very well be called ‘spectacular’ both for the much increased likelihood
that ALN-TTR02 will make it across the finish line and for the safety demonstration of Tekmira’s
SNALP delivery platform in general for which the major concern has always been safety,
not efficacy.

Importantly, the results revealed today show that the ~80% knockdown potency is maintained following an
aggregate of 119 doses of 0.3mg/kg ALN-TTR02 compared to an aggregate 38 doses
before. In the patient who has been on
therapy the longest, this was the case following 9 doses over half a year. The integrated knockdown level over time may have
indeed been slightly higher than 80% since TTR levels were measured at their
nadir, just before the next dose. One
can therefore conclude that the enhanced recovery from gene knockdown following
the second dose did not intensify over time and that sustained and consistent
knockdowns can be achieved over the long-term.

Regarding safety, just 3 instances of mild-moderate adverse
events were reported in the extension phase that were deemed possibly treatment-related. Probably only the 2
instances infusion reactions in a single subject call for attention. Even so, none of them were deemed severe enough that the infusion rate had to be slowed as
it is normally done. The other
mild-to-moderate AEs were an ‘increase of diarrhea’ and an 'impairment of taste'. Maybe not all that bad in a disease like FAP.

Further indicative of the tolerability of ALN-TTR02, Alnylam projects 27 out of the initial 30 patients to participate in the open-label extension study. First functional results from this OLE are expected to be reported by the end of 2014.

Disclosure: I could not resist but buy back some TKMR today based on the recognition that today’s data
represent a great de-risking of the SNALP LNP delivery platform the company depends
on.

Would think that this shown sustained safety/tolerability, would really boost the value of the EBV-program, as its mainly dependent on safety in humans. People are discounting this potential, i.e. significant near term (1yr>) revenues compared to current marketcap (perhaps even larger than current MC), way too steeply! In addition, this contiued shown safety (and efficacy) of the platform decreases the risk in the case that ARWR would run into some problems in its HBV trial.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.